|
A Phase II randomized, double-blind, dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified medical advice, calls or professional assistance using a genuine dr.. We aren't physicians. Always confer with your dr. on A Phase II randomized, double-blind, dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. A Phase II randomized, double-blind, dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus Clinical research trials and A Phase II randomized, double-blind, dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus medical trials happen in hundreds of localities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically measure the effectualness of new does drugs. The intent of the studies / undertakings is to answer particular human health questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to find cures for all kinds of circumstances, like A Phase II randomized, double-blind, dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus. A Phase II randomized, double-blind, dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus Clinical Trials and other clinical trials permit volunteers to acquire healthcare treatment options before they are available to the general public. Some times the subjects acquire professional assistance for free, and sometimes they are paid for their time. Sometimes there is a cost for a A Phase II randomized, double-blind, dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus clinical trial. Participants frequently obtain the most expert healthcare available for their A Phase II randomized, double-blind, dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus condition. Dangers are a reality, nevertheless, and can include more or frequent doctor calls, health risks (potentially life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Phase II randomized, double-blind, dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus  A Phase II randomized, double-blind, dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus
A Phase II randomized, double-blind, dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus
For Condition: Diabetes
Status: No longer recruiting
Sponsor(s): Hoffmann-La Roche ,
Synopsis: The objective of the study is to determine the dose(s) of Ro 205-2349 which, when compared to placebo, are efficacious, safe and tolerable in improving glycemic control in patients with type 2 diabetes. Doses of 2 to 5 mg/day will be studied.
Details:
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 35 Years/75 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Age 35 to 75 - Type 2 diabetes for longer than 3 months - HbA1c (glycosylated hemoglobin A1c) greater than 7.0% at screening - FPG (fasting plasma glucose) greater than 126 mg/dL at screening - BMI (body mass index) less than 40 kg/square meter Exclusion Criteria: - Type I diabetes - Type 2 diabetes patients currently treated with insulin - Type 2 diabetes patients curently or previously treated with Actos, Avandia ot Rezulin - FPG (fasting plasma glucose) greater than 270 mg/dL at baseline - Impaired liver or kidney function - Triglycerides greater than 600 mg/dL - Uncontrolled hypertension - Pregnant or lactating women - Women not using adequate contraception
Total Enrollment:
Location and Contact Information:
Additional Information:
Study ID Numbers: BM17151;
Study Start Date:
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00057304
Other Diabetes Studies:
1. Research Study in Patients with Persistent Macular Edema
2. Gene Therapy to Improve Wound Healing in Patients With Diabetes
3. Improving Compliance with Metformin
4. Improving Health Outcomes of Diabetic Veterans: A Diabetic Self-Management Program
5. Differential Metabolism of Dietary Fatty Acids
Related Studies:
Other Diabetes Clinical Trials
Other Clinical Trials
Other Tartu Clinical Trials
A Phase II randomized, double-blind, dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus
|
|
|
|
|
|
|
|
